Intravitreal anti-VEGF injection for the treatment of diabetic vitreous haemhorrage

Session Details

Session Title: Free Paper Session 16: Vascular Diseases & Diabetic Retinopathy IV

Session Date/Time: Friday 08/09/2017 | 16:30-18:00

Paper Time: 17:00

Venue: Room 114

First Author: : M.Dunaieva UKRAINE

Co Author(s): :    S. Ustimenko   L. Bereznyuk   S. Fokina                       

Abstract Details


To determine the efficiency of single intravitreal Ranibizumab or Aflibercept injection in patients with a vitreous haemhorrage (VH) secondary to proliferative diabetic retinopathy (PDR).


The stusy includes 46 patients who were treated in Dnipro Eye Hospital between January 2014 and January 2017 with a new VH secondary to PDR.


The patients were divided into two groups. The first group 17 patients (17 eyes) received 0.5 mg Ranibizumab intevireal and the second group 14 patients (14 eyes) received intravitreal Aflibercept 2.0 mg. The control group consists 15 patients (15 eyes). VH clearance time was defined as the time until primary vessels in the posterior pole and the optic disc were clearly visible. Patients who were treated by IVB injection and those who were followed without IV therapy were compared in terms of VA change and final VA, VH clearance time and rate of surgical intervention.


VH clearance time was 2.3±1.1 months in group 1, 2.6±1.8 months in group 2 and 3.4±2.6 months in control group. Recurrent haemhorrage developed during follow-up in 4 eyes from group 1 and 4 eyes from group 2 and 11 eye from control group. The 20,1% from group 1 and 23,5% from group 2 and 45.6 % from control group underwent PPV due to persistent or recurrent VH (p=0.048). The amount of patients that underwent PPV was significantly higher in control group. The difference between initial and final VA accordin Snellen chart was 0.3±0,1 in group 1, 0.35±0,11 in group 2 and 0,18±0.09 in control group (p=0.1).


This study showed important role IV anti-VEGF injections in the management of patients with VH secondary to PDR. IV injections was found effective in terms of reducing, the need for surgery, but it did not impact final VA. No differences between intravitreal Ranibizumab and Aflibercept were found.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy